{"schema_version":"secwatch.filing_event.v1","accession":"0000105770-22-000014","form_type":"8-K","ticker":"WST","cik":"0000105770","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2022-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.542276+00:00","generated_at":"2026-06-26T03:03:55.310221+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"West Pharma Q1 net sales $720M (+7.4%), adj. EPS $2.30; raises FY2022 adj. EPS guidance","bullets":["Net sales $720.0M (+7.4% YoY); organic sales growth 11.0%.","Reported diluted EPS $2.29 (+15.1%), adjusted diluted EPS $2.30 (+12.2%).","Raises FY2022 adjusted EPS guidance to $9.30-$9.45 from $9.20-$9.35; reaffirms net sales $3.05B-$3.075B.","Q3 dividend $0.18/share, payable Aug 3, record Jul 20; repurchased 390k shares for $147.1M.","Proprietary Products segment sales $601.3M (+10.6%); HVP organic growth double-digit."],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-22-000014","json":"https://secwatch.observer/filing/0000105770-22-000014.json","markdown":"https://secwatch.observer/filing/0000105770-22-000014.md","text":"https://secwatch.observer/filing/0000105770-22-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577022000014/0000105770-22-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577022000014/wst-20220428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T03:03:55.310221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}